131 related articles for article (PubMed ID: 8045141)
1. An evaluation of the hemodynamic effects of HA-1A human monoclonal antibody.
Kett DH; Quartin AA; Sprung CL; Fisher CJ; Peña MA; Heard SO; Zimmerman JL; Albertson TE; Panacek EA; Eidelman LA
Crit Care Med; 1994 Aug; 22(8):1227-34. PubMed ID: 8045141
[TBL] [Abstract][Full Text] [Related]
2. Treatment of gram-negative bacteremia and septic shock with HA-1A human monoclonal antibody against endotoxin. A randomized, double-blind, placebo-controlled trial. The HA-1A Sepsis Study Group.
Ziegler EJ; Fisher CJ; Sprung CL; Straube RC; Sadoff JC; Foulke GE; Wortel CH; Fink MP; Dellinger RP; Teng NN
N Engl J Med; 1991 Feb; 324(7):429-36. PubMed ID: 1988827
[TBL] [Abstract][Full Text] [Related]
3. Treatment of septic shock with human monoclonal antibody HA-1A. A randomized, double-blind, placebo-controlled trial. CHESS Trial Study Group.
McCloskey RV; Straube RC; Sanders C; Smith SM; Smith CR
Ann Intern Med; 1994 Jul; 121(1):1-5. PubMed ID: 8198341
[TBL] [Abstract][Full Text] [Related]
4. A controlled trial of HA-1A in a canine model of gram-negative septic shock.
Quezado ZM; Natanson C; Alling DW; Banks SM; Koev CA; Elin RJ; Hosseini JM; Bacher JD; Danner RL; Hoffman WD
JAMA; 1993 May; 269(17):2221-7. PubMed ID: 8474201
[TBL] [Abstract][Full Text] [Related]
5. Effectiveness of a human monoclonal anti-endotoxin antibody (HA-1A) in gram-negative sepsis: relationship to endotoxin and cytokine levels.
Wortel CH; von der Möhlen MA; van Deventer SJ; Sprung CL; Jastremski M; Lubbers MJ; Smith CR; Allen IE; ten Cate JW
J Infect Dis; 1992 Dec; 166(6):1367-74. PubMed ID: 1431255
[TBL] [Abstract][Full Text] [Related]
6. Introduction of new technology into critical care practice: a history of HA-1A human monoclonal antibody against endotoxin.
Luce JM
Crit Care Med; 1993 Aug; 21(8):1233-41. PubMed ID: 8339592
[TBL] [Abstract][Full Text] [Related]
7. The influence of clinical study design on cost-effectiveness projections for the treatment of gram-negative sepsis with human anti-endotoxin antibody.
Linden PK; Angus DC; Chelluri L; Branch RA
J Crit Care; 1995 Dec; 10(4):154-64. PubMed ID: 8924965
[TBL] [Abstract][Full Text] [Related]
8. Projected impact of monoclonal anti-endotoxin antibody therapy.
Bates DW; Lee TH
Arch Intern Med; 1994 Jun; 154(11):1241-9. PubMed ID: 8203991
[TBL] [Abstract][Full Text] [Related]
9. Human monoclonal antibody against endotoxin.
Zarowitz BJ
DICP; 1991; 25(7-8):778-83. PubMed ID: 1949939
[TBL] [Abstract][Full Text] [Related]
10. A second large controlled clinical study of E5, a monoclonal antibody to endotoxin: results of a prospective, multicenter, randomized, controlled trial. The E5 Sepsis Study Group.
Bone RC; Balk RA; Fein AM; Perl TM; Wenzel RP; Reines HD; Quenzer RW; Iberti TJ; Macintyre N; Schein RM
Crit Care Med; 1995 Jun; 23(6):994-1006. PubMed ID: 7774238
[TBL] [Abstract][Full Text] [Related]
11. Anti-endotoxin therapy in primate bacteremia with HA-1A and BPI.
Rogy MA; Moldawer LL; Oldenburg HS; Thompson WA; Montegut WJ; Stackpole SA; Kumar A; Palladino MA; Marra MN; Lowry SF
Ann Surg; 1994 Jul; 220(1):77-85. PubMed ID: 8024362
[TBL] [Abstract][Full Text] [Related]
12. [Preventive interruption of the administration of HA-1A monoclonal antibody against endotoxin].
Torrabadella de Reynoso P; Trilla A; Salgado A; Ribas J
Med Clin (Barc); 1993 Apr; 100(13):518. PubMed ID: 8479241
[No Abstract] [Full Text] [Related]
13. [Immunotherapy using the anti-endotoxin antibody HA-1A (Centoxin) in patients with sepsis syndrome; fair results following protocol selection of patients].
Costongs LG; Speelman P; van Lieshout JJ; van Deventer SJ; Lubbers MJ; Schipper HG
Ned Tijdschr Geneeskd; 1993 Feb; 137(7):355-60. PubMed ID: 8437634
[TBL] [Abstract][Full Text] [Related]
14. Adoptive immunotherapy of gram-negative sepsis: use of monoclonal antibodies to lipopolysaccharide.
Fink MP
Crit Care Med; 1993 Feb; 21(2 Suppl):S32-9. PubMed ID: 8428494
[TBL] [Abstract][Full Text] [Related]
15. [Immunotherapy using the anti-endotoxin antibody HA-1A in patients with sepsis syndrome; good results in relation to treatment with placebo].
Wortel CH; von der Möhlen MA; van Deventer SJ; Schipper HG; Lorijn RH; ten Cate JW
Ned Tijdschr Geneeskd; 1993 Feb; 137(7):350-4. PubMed ID: 8437633
[TBL] [Abstract][Full Text] [Related]
16. Initial evaluation of human monoclonal anti-lipid A antibody (HA-1A) in patients with sepsis syndrome.
Fisher CJ; Zimmerman J; Khazaeli MB; Albertson TE; Dellinger RP; Panacek EA; Foulke GE; Dating C; Smith CR; LoBuglio AF
Crit Care Med; 1990 Dec; 18(12):1311-5. PubMed ID: 2245602
[TBL] [Abstract][Full Text] [Related]
17. HA-1A in septic patients with ARDS: results from the pivotal trial.
Bigatello LM; Greene RE; Sprung CL; Panacek EA; Straube RC; Zimmerman JL; Maunder RJ; Lanken PN; Pile-Spellmann E; Stanek KS
Intensive Care Med; 1994 May; 20(5):328-34. PubMed ID: 7930026
[TBL] [Abstract][Full Text] [Related]
18. Confirmatory platelet-activating factor receptor antagonist trial in patients with severe gram-negative bacterial sepsis: a phase III, randomized, double-blind, placebo-controlled, multicenter trial. BN 52021 Sepsis Investigator Group.
Dhainaut JF; Tenaillon A; Hemmer M; Damas P; Le Tulzo Y; Radermacher P; Schaller MD; Sollet JP; Wolff M; Holzapfel L; Zeni F; Vedrinne JM; de Vathaire F; Gourlay ML; Guinot P; Mira JP
Crit Care Med; 1998 Dec; 26(12):1963-71. PubMed ID: 9875905
[TBL] [Abstract][Full Text] [Related]
19. Influence of N-acetylcysteine on indirect indicators of tissue oxygenation in septic shock patients: results from a prospective, randomized, double-blind study.
Spies CD; Reinhart K; Witt I; Meier-Hellmann A; Hannemann L; Bredle DL; Schaffartzik W
Crit Care Med; 1994 Nov; 22(11):1738-46. PubMed ID: 7956276
[TBL] [Abstract][Full Text] [Related]
20. Gram-negative sepsis, the sepsis syndrome, and the role of antiendotoxin monoclonal antibodies.
Barriere SL; Guglielmo BJ
Clin Pharm; 1992 Mar; 11(3):223-35. PubMed ID: 1611812
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
